Epilepsy is prevalent and often medically intractable in Angelman syndrome (AS). AS mouse model (Ube3a
Introduction
Angelman syndrome (AS) is a neurodevelopmental disorder caused by maternal deficiency of the E6-AP ubiquitin ligase (UBE3A) associated with a deletion of chromosome 15q11-q13 region, paternal uniparental disomy, point mutation in UBE3A or an imprinting defect (Buiting et al. 2016; Jiang et al. 1999 ). Clinically, epilepsy or seizure disorder is one of the most common (80 to 95%) and devastating features in AS, which starts before 3 years of age in most cases (Fiumara et al. 2010; Thibert et al. 2013) . The seizure phenotype is reported to be more prominent in AS patients with a maternal deletion of chromosomal 15q11-q13 region, presumably due to the haploinsufficiency of a cluster of GABA receptors including GABRB3 in the distal end (Dan 2009; DeLorey et al. 1998; Egawa et al. 2008 ). The electroencephalogram (EEG) in AS patients has a characteristic pattern of large-amplitude slow-spike waves at 1-2 or 4-6 Hz (Sidorov et al. 2017; Vendrame et al. 2012) . A significant fraction of clinical seizures is medically intractable and the quality of life is significantly compromised in these individuals (Tan and Bird 2016) .
The epilepsy in AS is mostly generalized but partial epilepsy has also been frequently observed. The specific clinical seizures may vary from atypical absence, myoclonic, generalized tonic-clonic, tonic and atonic seizures (Dan 2009; Tan and Bird 2016) . The genotype and phenotype correlation for seizure presentation has been described. Chromosomal deletion results in more severe seizure than other causes including uniparental disomy, point mutation in UBE3A gene, and an imprinting defect (Thibert et al. 2013 ). Current treatment is symptomatic with one or multiple drugs at a time. Valporic acid and clonazepam are most commonly prescribed but others such as levetiracetam, lamotrigine and clobazam have also been used frequently (Shaaya et al. 2016; Thibert et al. 2009 ). The molecular target therapy of reactivating UBE3A from the paternal chromosome has been investigated in animal model but remains to be seen if this is feasible in human (Buiting et al. 2016; Huang et al. 2012; Meng et al. 2015) .
Despite the substantial progress in understanding the molecular basis and synaptic mechanism of AS, the mechanism underlying seizure caused by the UBE3A deficiency remains poorly understood. The AS mouse model (Ube3a m −/p + ) recapitulates the major clinical features of AS including abnormal EEG in hippocampus and neocortex (Jiang et al. 1998; Mandel-Brehm et al. 2015; Miura et al. 2002) . Increased susceptibility of audiogenic seizures has been reported in AS model and they are mouse strain and age dependent (Jiang et al. 1998; Jiang et al., 
